CAJ | 학술논문

晚期非小细胞肺癌（NSCLC）的治疗需首先明确其组织学类型与分子学特征。若存在表皮生长因子受体（EGFR）基因突变或渐变性淋巴瘤激酶（ALK）基因融合，应首选分子靶向药物治疗。但分子靶向治疗药物并未改善晚期患者的总生存，如何提高晚期NSCLC患者的总生存是目前临床医生关注的热点。表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）与含铂双药交替使用模式作为晚期NSCLC的一线治疗方案，可能将明显延长EGFR阳性突变患者总生存时间。本文就小分子酪氨酸激酶抑制剂联合化疗治疗NSCLC患者、方式及其疗效的研究进展进行综述。
만기비소세포폐암（NSCLC）적치료수수선명학기조직학류형여분자학특정。약존재표피생장인자수체（EGFR）기인돌변혹점변성림파류격매（ALK）기인융합，응수선분자파향약물치료。단분자파향치료약물병미개선만기환자적총생존，여하제고만기NSCLC환자적총생존시목전림상의생관주적열점。표피생장인자수체락안산격매억제제（EGFR-TKIs）여함박쌍약교체사용모식작위만기NSCLC적일선치료방안，가능장명현연장EGFR양성돌변환자총생존시간。본문취소분자락안산격매억제제연합화료치료NSCLC환자、방식급기료효적연구진전진행종술。
Currently, histological and molecular methods are considered for the treatment of advanced non-small cell lung cancer (NSCLC). Single-agent epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) and anaplastic lymphoma kinase in-hibitors (ALK-TKIs) have been used as standard first-line therapies for patients with active EGFR mutation and ALK rearrangement, re-spectively. However, to date, the single-agent EGFR-TKIs as the first-line therapy for patients with known EGFR mutations has been demonstrated to provide a prolonged progression-free survival but does not affect overall survival (OS). Physicians these days focus on improving the OS of patients with advanced NSCLC. To patients with EGFR mutation, combining and maintaining EGFR-TKIs with chemotherapy could be a promising approach. In this article, various ways of combining EGFR-TKIs with chemotherapy were explored.